The study will examine the safety and efficacy of Prodisc C in cervical disc injury, according to a December news release.
The trial aims to demonstrate that Prodisc C SK and Prodisc C Vivo are at least as safe and effective as Mobi-C — a similar cervical disc prosthesis on the market — to treat symptomatic cervical disc disease at two contiguous levels from C3 to C7.
Masson Spine Institute is now enrolling patients in the clinical trial.
More articles on practice management:
How CMS’ changes will affect spine surgeons in 2021 — Prior authorization, fee cuts & more
Former orthopedic practice owner gets 5 years in prison for illegally prescribing opioids
Surgeons’ brand exceeds patient outcomes — How you should build your practice’s brand
